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a b s t r a c t
Persistenceof antibodies after a single doseof Tdapvaccine (tetanus, diphtheria, and5-component acellu-
lar pertussis vaccine)was evaluated in a follow-up studyof adolescents (N=324) and adults (N=644)who
had received Tdap in earlier clinical trials. Outcome measures were seroprotection (tetanus and diphthe-
ria) or seropositivity (pertussis) and geometric mean concentrations. Humoral immune responses to all
antigens were robust 1 month after initial immunization, decreased at subsequent measurements, but
continued to exceed pre-immunization levels 1, 3, 5, and 10 years later.ertussis
accine
erology
Protective levels of diphtheria and tetanus antitoxin persisted in 99.3% of adolescents 10 years after a
booster dose of Tdap. Seropositivity to 1 or more pertussis antigens also persisted in most adolescents for
10 years. Although tetanus antitoxin responses were similar in adults to those observed in adolescents,
diphtheria antitoxin titers were lower, reﬂecting the fact that a smaller proportion of adults had received
diphtheria toxoid in the previous 10 years compared to adolescents. These data will contribute to the
selection of the optimal interval for repeat doses of Tdap.. Introduction
Despite widespread childhood immunization against pertussis,
he reported number of cases of pertussis in the US continues to
ncrease: 16,858 cases reported in 2009 and a provisional total of
1,291 in 2010 compared to a mean of 11,929 between 1999 and
007 [1,2]. An outbreak in California during 2010 accounted for
4.5% of reported cases [1,3].
Between 2000 and 2009, the majority of cases reported in
he USA have occurred in adolescents and adults, consistent with
aningprotection after childhoodvaccination and suboptimal cov-
rage rates of booster doses of combined tetanus and reduced
iphtheria toxoids and acellular pertussis vaccine [Tdap] in ado-
escents and adults [3–7]. Although the reported proportion of
dolescents receiving Tdap has increased since vaccine licensure in
005, only 56% of adolescents had received a dose of Tdap vaccine
y 2009 [8]. The increased incidence of pertussis in 2010 occurred
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in all age groups, reﬂecting gaps in coveragenot only in adolescents,
but also in infants and young children.
In addition to the morbidity of pertussis in adolescents and
adults, infected adolescents and adults are the major source of
transmission of pertussis to infants, especially those less than 6
months of age who are too young to have been protected by vacci-
nation [7,10–14]. Young infants are at the highest risk of morbidity
and mortality from pertussis [7,15]. Immunization of adolescents
and adults against pertussis has been recommended not only
to reduce the morbidity caused by the disease, but to reduce
household exposure of vulnerable infants to pertussis [2,16–20].
Administration of Tdap boosters to adolescents 14–16 years of age
has now been added to routine pertussis immunization of infants
and children in several provinces of Canada, and the incidence of
reported pertussis decreased dramatically in all age groups includ-
ing adolescents [21].
Although boosters of tetanus and diphtheria toxoids are rec-
ommended every 10 years, there are limited data available on the
long-term persistence of antibody levels induced by Tdap com-
bination vaccines [22–27]. We have previously reported on the
persistence of antibodies at 1, 3, and 5 years after vaccination
of adolescent and adults with Tdap [25]. The measurement of
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Table 1
Participant disposition, N (%).
Pre- 1 month 1 year 3 years 5 years 10 years
Adolescents in Study 1a
Eligible to participate 55 (100) 55 (100) 55 (100) 55 (100) 55 (100) 55 (100)
Provided blood sample 55 (100) 55 (100) 34 (61.8) 26 (47.3) 25 (45.5) 15 (27.3)
Participant in diphtheria analysis 55 (100) 55 (100) 34 (61.8) 26 (47.3) 24 (43.6) 15 (27.3)
Participant in tetanus analysis 55  (100) 55 (100) 34 (61.8) 26 (47.3) 25 (45.5) 15 (27.3)
Participant in pertussis analysisb 55 (100) 55 (100) 34 (61.8) 26 (47.3) 25 (45.5) 15 (27.3)
Adolescents in Study 2c
Eligible to participate 269 (100) 269 (100) 269 (100) 269 (100) 269 (100) 269 (100)
Provided blood sample 267 (99.3) 267 (99.3) 154 (57.2) 165 (61.3) 165 (61.3) 150 (55.8)
Participant in diphtheria analysis 267 (99.3) 267 (99.3) 154 (57.2) 165 (61.3) 163 (60.6) 149 (55.4)
Participant in tetanus analysis 267  (99.3) 267 (99.3) 154 (57.2) 164 (61.0) 161 (59.9) 148 (55.0)
Participant in pertussis analysis 267 (99.3) 267 (99.3) 154 (57.2) 165 (61.3) 165 (61.3) 150 (55.8)
Adults in Study 1d
Eligible to participate 394 (100) 394 (100) 394 (100) 394 (100) 394 (100) 394 (100)
Provided blood sample 394 (100) 391 (99.2) 166 (42.1) 182 (46.2) 164 (41.6) 129 (32.7)
Participant in diphtheria analysis 394 (100) 391 (99.2) 164 (41.6) 177 (44.9) 178 (39.1) 120 (30.5)
Participant in tetanus analysis 394 (100) 391 (99.2) 162 (41.1) 175 (44.4) 176 (37.8) 116 (29.4)
Participant in pertussis analysise 394 (100) 391 (99.2) 166 (42.1) 182 (46.2) 182 (41.6) 127 (32.3)
Adults in Study 3f
Eligible to participate 250 (100) 250 (100) 250 (100) 250 (100) 250 (100) 250 (100)
Provided blood sample 244 (97.6) 244 (97.6) 23 (9.2) 94 (37.6) 90 (36.0) 62 (24.8)
Participant in diphtheria analysis 243 (97.2) 243 (97.2) 23 (9.2) 94 (37.6) 89 (35.6) 62 (24.8)
Participant in tetanus analysis 243 (97.2) 244 (97.2) 23 (9.2) 94 (37.2) 88 (34.8) 62 (24.8)
Participant in pertussis analysisg 121 (48.4) 121 (48.4) 11 (4.4) 48 (19.2) 46 (18.4) 32 (12.8)
a Adolescents, 11–17 years of age, received one of 3 lots of Tdap at time 0.
b For pertussis antigens analysis, 52 adolescents were included pre-immunization.
c Adolescents, 11–13 years of age, Group 1 received Tdap and Hepatitis B vaccine at 1, 2, and 7 months; Group 2 received Tdap and Hepatitis B vaccine at 0, and then
Hepatitis B vaccine at 1 and 6 months.
d Adults, 18–54 years of age, 397 adults Groups 3–5 received one of 3 lots of Tdap at time 0.
e For pertussis antigens analysis, 394 adults were included pre-immunization.
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ntibody persistence elicited by Tdap 10 years post-immunization
ay aid in formulating recommendations concerning the timing of
ooster doses of Tdap in adolescents and adults.
. Materials and methods
.1.  Study design
Three  studies assessing the safety and immunogenicity of Tdap
see details below) have been conducted in Canada [25–27]. Study
 compared 3 lots of Tdap in adolescents and adults 11–54 years
f age; Study 2 compared a group of adolescents 11–13 years of
ge given Tdap and Hepatitis B (HepB) to a group who  received
he vaccines 1 month apart; and Study 3 compared Tdap versus Td
accine given to participants 19–60 years of age [25] (see Table 1).
The adolescent and adult Tdap recipients from those studies
ere contacted to provide sera to assess antibody persistence
licited by Tdap 5 years post-immunization [25]. The 3 study groups
eﬁned in that publication were recontacted to conduct a similar
nalysis 10 years post-immunization.
.2.  Participants and study sites
Among the original study sites selected to participate in this
ollow-up study selected on the basis of the unlikelihood of site
losure, projected availability, workload, and logistical considera-
ions, participants in the original study were eligible to enroll in the
ollow-up study and provide blood samples at 1, 3, 5, and 10 years
ost-vaccination. All participants were eligible except for those in
tudy 1 who did not receive Tdap. All trials were conducted fol-
owing the principles outlined in the Declaration of Helsinki, good
linical practice, and the International Conference on Harmoniza-
ion guidelines. 6 received Tdap at time 0.
2.3. Serological assays
Anti-tetanus  antibody concentrations were measured by
enzyme-linked immunosorbent assay (ELISA); anti-diphtheria
antibody concentrations were measured by serum neutraliza-
tion assay (SN). Concentrations were expressed as International
Units (IU)/ml, standardized against World Health Organiza-
tion reference sera. For both anti-diphtheria and anti-tetanus
antibody, results were reported as the proportions of partici-
pants with serum levels of ≥0.01 IU/ml and ≥0.1 IU/ml; these
levels are generally accepted as consistent with protection
[28,29].
Antibody levels to pertussis toxoid [PT], ﬁlamentous hemagglu-
tinin [FHA], pertactin [PRN], and ﬁmbriae types 2&3 [FIM] were
determined by ELISA and were expressed in ELISA units (EU/ml).
Since there are no universally accepted antibody correlates of pro-
tection for pertussis, seropositivity was  evaluated by determining
the proportion having antibody levels ≥ the lower limit of quanti-
tation (LLOQ) or 4 times the LLOQ (LLOQ × 4) [30,22]. The LLOQs
for the assays performed at Sanoﬁ Pasteur Clinical Immunology
Platform in Canada (CIP-CA) were 5 EU/ml for PT, 3 EU/ml for FHA,
3 EU/ml for PRN, and 17 EU/ml for FIM and for the assays performed
at Sanoﬁ Pasteur Global Clinical Immunology (GCI) in Swiftwater,
Pennsylvania were 4 EU/ml for PT, PRN, and FIM and 3 EU/ml for
FHA.
Throughout the studies, serological assays were performed
at 2 locations: GCI for diphtheria and tetanus assays at 5-
years samples and all assays at 10-years samples; CIP-CA for
all assays at baseline, 1-month, 1- and 3-year post-vaccination
samples and for the pertussis assays for the 5-years samples.
Pre-immunization and 1 month post-immunization sera were
assayed in parallel; follow-up sera were assayed separately
shortly after collection at the 1, 3, 5, and 10-years sampling
times.
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Fig. 1. Geometric mean concentrations of diphtheria and 
.4. Vaccines
The Tdap vaccine (Adacel®, Sanoﬁ Pasteur Limited) contains 5
f (limit of ﬂocculation units) tetanus toxoid (T), 2 Lf diphtheria
oxoid (d), 2.5 g PT, 5 g FHA, 3 g PRN, and 5 g FIM. The Td
accine used as a control in the adult active comparator study (Td
dsorbed Vaccine, Sanoﬁ Pasteur Ltd.) contains 5 Lf tetanus toxoid
nd 2 Lf diphtheria toxoid. These Tdap and Td vaccines each con-
ain an adjuvant consisting of 1.5 mg  aluminum phosphate (0.33 mg
luminum).
.5. Statistical analysis
Serological  results were presented as geometric mean con-
entrations (GMCs) with 95% conﬁdence intervals (CIs) for all
ntibodies, seroprotection rates (≥0.01 and ≥0.1 IU/ml) with 95%
Is for tetanus and diphtheria antitoxin, and seropositivity rates
LLOQ and LLOQ × 4) with 95% CIs for pertussis antibodies. The
tatistical analysis included all participants who  provided a blood
ample at all follow-up time points. To compare with previous
eports, results are presented from the following time points: pre-
mmunization, 1 month, 1, 3, 5, and 10 years post-immunization.
ndividuals were excluded from analysis if they received any vac-
ine containing tetanus, diphtheria, or pertussis antigens after the
nitial study vaccination or were clinically diagnosed or laboratory-
onﬁrmed to have had pertussis within the 2 years prior to each
ollow-up visit.
Adolescents in school were more likely than adults to have
eceived combined diphtheria and tetanus toxoids and pertussis
accine in the 10–15 years prior to enrollment in these studies;
herefore, antibody responses were analyzed separately for ado-
escents and adults.
.  Results
.1. Participants
The numbers of participants enrolled and followed at each time
eriod are presented in Table 1. The majority of participants who
id not return to provide blood samples were lost to follow up. Only
 participants were not included in the 10 years follow-up analy-
es because they had received a tetanus and/or diphtheria and/orTetanus
s antitoxin after immunization of adolescents with Tdap.
pertussis  vaccine since the 5-year time point. Of the 55 adolescents
enrolled in Study 1 who received vaccine from 1 of 3 lots of Tdap, 15
(27.3%) were seen at 10 years post-immunization. In Study 2, of 269
adolescents enrolled and allocated to receive Tdap and Hepatitis B
vaccine concurrently or 1 month apart, 150 (55.8%) provided sera
samples at 10 years. Because antibody results were comparable in
the 2 arms of Study 2, the results were combined.
The 394 adults in Study 1 also received 1 of 3 lots of Tdap while
250 in Study 3 received either Td or Tdap. Only the 121 adults who
received Tdap in Study 3 were recruited for the 10-year follow up.
At 10 years, 129 (32.7%) adults in Study 1 and 62 (24.8%) adults in
Study 3 were seen in follow-up. The attrition rate by 10 years post-
immunization was greater among adults than adolescents (Table 1).
3.2. Persistence of antibody responses in adolescents
All but 1 adolescent in Studies 1 and 2 had protective levels of
anti-diphtheria antibody (≥0.01 IU/ml) and 100% had ≥0.01 IU/ml
of anti-tetanus antibody at 10 years post-immunization with Tdap
(Table 2). Over 86% had anti-diphtheria levels ≥0.1 IU/ml  and >99%
had anti-tetanus levels ≥0.1 IU/ml. GMCs of both anti-diphtheria
and anti-tetanus demonstrated the expected rapid decline after the
peak response at 1 month post-immunization, but between 1 year
and 10 years post vaccination, GMCs plateaued and remained above
or at the pre-immunization level (Fig. 1).
Antibody persistence varied somewhat between the different
pertussis antibodies at 10 years after Tdap vaccination. The pro-
portions of adolescents with antibody levels ≥LLOQ against FHA,
PRN, and FIM remained high throughout the 10-year follow-up
period and were 94.7–100% at 10 years. Proportions seropositive
for anti-PT were similar to those for the other antibodies up to
5 years post-vaccination, but between 5 years and 10 years post-
vaccination the percentage seropositive for anti-PT decreased more
rapidly, reaching 69.8–78.6% (Table 3). The GMCs of all pertussis
antibodies rapidly declined between 1 month and 1 year post-
vaccination followed by a much slower decline between 1 year and
10 years (Fig. 2A).3.3.  Persistence of antibody responses in adults
Over 98% of adults achieved ≥0.01 IU/ml of diphtheria antitoxin
1 month post-vaccination with Tdap or Td (Table 4). Diphtheria
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Table 2
Percentage of adolescents achieving tetanus and diphtheria seroprotection after immunization with Tdap, % (N*).
Pre- 1 month 1 year 3 years 5 years 10 years
Diphtheria antitoxin
≥0.01  IU/ml
Tdap (Study 1) 94.5 (55) 100 (55) 100 (34) 100 (26) 100 (24) 100 (15)
Tdap  (Study 2) 100 (267) 100 (267) 100 (154) 100 (165) 100 (163) 99.3 (149)
≥0.10  IU/ml
Tdap (Study 1) 65.5 (55) 100 (55) 97.1 (34) 96.2 (26) 91.7 (24) 86.7 (15)
Tdap  (Study 2) 82.8 (267) 100 (267) 98.7 (154) 98.8 (165) 92.0 (163) 88.6 (149)
Tetanus  antitoxin
≥0.01  IU/ml
Tdap (Study 1) 100 (55) 100 (55) 100 (34) 100 (26) 100 (24) 100 (15)
Tdap  (Study 2) 100 (267) 100 (267) 100 (154) 100 (164) 100 (163) 100 (148)
≥0.10  IU/ml
Tdap (Study 1) 94.5 (55) 100 (55) 100 (34) 100 (26) 100 (24) 100 (15)
Tdap  (Study 2) 98.9 (267) 100 (267) 100 (154) 100 (164) 100 (163) 99.3 (148)
Table 3
Percentage of adolescents achieving seropositivity to pertussis antigens after immunization with Tdap,a % (N).
Pre- 1 month 1 year 3 years 5 years 10 years
≥LLOQb
PT
Tdap (Study 1) 80.8 (55) 100 (55) 100 (34) 96.2 (26) 100 (25) 78.6 (14)
Tdap  + HepB (Study 2) 68.2 (267) 99.3 (267) 97.4 (154) 92.7 (165) 93.3 (165) 69.8 (139)
FHA
Tdap  (Study 1) 92.7 (55) 100 (55) 100 (34) 100 (26) 100 (25) 100 (15)
Tdap  + HepB (Study 2) 96.3 (267) 100 (267) 99.4 (154) 98.8 (165) 100 (165) 100 (150)
PRN
Tdap  (Study 1) 74.5 (55) 100 (55) 100 (34) 100 (26) 100 (25) 100 (15)
Tdap  + HepB (Study 2) 75.7 (267) 100 (267) 98.1 (154) 97.6 (165) 98.8 (165) 94.7 (150)
FIM
Tdap  (Study 1) 78.2 (55) 100 (55) 100 (34) 100 (26) 100 (25) 100 (25)
Tdap  + HepB (Study 2) 76.8 (267) 100 (267) 98.1 (154) 97.6 (165) 98.8 (165) 94.7 (150)
≥4  × LLOQ
PT
Tdap (Study 1) 44.2 (52) 100 (55) 91.2 (34) 84.6 (26) 88.0 (25) 64.3 (14)
Tdap  + HepB (Study 2) 34.1 (267) 96.6 (267) 80.5 (154) 69.7 (165) 62.4 (165) 65.3 (139)
FHA
Tdap  (Study 1) 81.8 (55) 100 (55) 100 (34) 88.5 (26) 92.0 (25) 80.0 (15)
Tdap  + HepB (Study 2) 84.3 (267) 100 (267) 98.7 (154) 98.2 (165) 98.8 (165) 88.0 (150)
PRN
Tdap  (Study 1) 49.1 (55) 100 (55) 97.1 (34) 96.2 (26) 84.0 (25) 86.7 (15)
Tdap  + HepB (Study 2) 39.3 (267) 98.9 (267) 90.3 (154) 87.9 (165) 88.5 (165) 65.3 (150)
FIM
Tdap  (Study 1) 49.1 (55) 100 (55) 97.1 (34) 96.2 (26) 88.0 (25) 100 (15)
Tdap  + HepB (Study 2) 39.3 (267) 99.3 (267) 94.2 (154) 84.2 (165) 83.0 (165) 98.0 (150)
a Expressed as the percentage of participants with antibodies at or above the lower limit of quantitation or LLOQ × 4.
b LLOQ = 5 EU/ml for PT, 3 EU/ml for FHA, 3 EU/ml for PRN, and 17 EU/ml for FIM for pre-, 1 month, 1, 3, 5 years; for 10 years, LLOQ = 4 EU/ml for PT, PRN, and FIM;
LOQ = 3 EU/ml for FHA.
Table  4
Percentage of adults achieving tetanus and diphtheria seroprotection after immunization with Tdap, % (N*).
Pre- 1 month 1 year 3 years 5 years 10 years
Diphtheria antitoxin
≥0.01  IU/ml
Tdap (Study 1) 85.3 (394) 98.0 (391) 99.4 (164) 100 (177) 96.8 (154) 96.7 (120)
Tdap  (Study 3) 86.0 (121) 98.3 (121) 100 (11) 100 (48) 86.7 (45) 93.8 (32)
Td  (Study 3) 88.5 (122) 99.2 (122) 100 (12) 100 (46) 88.6 (44) 83.3 (30)
≥0.10  IU/ml
Tdap (Study 1) 39.1 (394) 89.8 (391) 78.7 (164) 70.6 (177) 60.4 (154) 64.2 (120)
Tdap  (Study 2) 48.8 (121) 91.7 (121) 100 (11) 58.3 (48) 51.1 (45) 46.9 (32)
Td  (Study 3) 50.0 (122) 97.5 (122) 83.3 (12) 65.2 (46) 56.8 (44) 56.7 (30)
Tetanus  antitoxin
≥0.01  IU/ml
Tdap (Study 1) 100 (393) 100 (391) 100 (162) 100 (174) 100 (149) 99,1 (116)
Tdap  (Study 3) 100 (121) 100 (121) 100 (11) 100 (47) 100 (44) 100 (32)
Td  (Study 3) 100 (122) 100 (122) 100 (12) 97.8 (46) 100 (43) 100 (30)
≥0.10  IU/ml
Tdap (Study 1) 92.2  (393) 100 (391) 100 (162) 100 (174) 99.3 (149) 99,1 (116)
Tdap  (Study 2) 96.7  (121) 100 (121) 100 (11) 100 (47) 97.7 (44) 100 (32)
Td  (Study 3) 93.4 (122) 100 (122) 100 (12) 95.7 (46) 97.7 (43) 96.7 (30)
N* is number of samples tested at each time interval.
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ntitoxin levels declined more rapidly in adults than in adolescents.
t 10 years post-vaccination, 93.8–96.7% of adults given Tdap had
0.01 IU/ml, compared to 83.3% of those receiving Td. As observed
n adolescents, tetanus antitoxin levels remained at seroprotective
evels in almost all recipients (Table 4 and Fig. 3).
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Persistence of antibodies to pertussis antigens in adults was
similar to that seen in adolescents (Table 5). At 10 years
post-vaccination with Tdap, antibody ≥LLOQ was  observed in
most participants, with lower percentages seropositive for PT
(82.1–92.7%) than FHA (100%), PRN (>93%) and FIM (>98%). GMCs
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nus antitoxin after immunization of adults with Tdap.
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Table 5
Percentage of adults achieving seropositivity after immunization with Tdap,a % (N).
Pre- 1 month 1 year 3 years 5 years 10 years
≥LLOQb
PT
Tdap (Study 1) 68.0 (387) 100 (390) 98.8 (166) 96.2 (182) 98.2 (164) 92.7 (109)
Tdap  (Study 3) 76.0 (121) 100 (121) 100 (11) 95.8 (48) 100 (46) 82.1 (28)
FHA
Tdap  (Study 1) 93.7 (394) 100 (391) 99.4 (166) 100 (182) 100 (164) 100 (127)
Tdap  (Study 3) 91.7 (121) 100 (121) 100 (11) 100 (48) 100 (46) 100 (32)
PRN
Tdap  (Study 1) 60.2 (394) 99.2 (391) 97.6 (166) 99.4 (181) 93.9 (164) 93.8 (129)
Tdap  (Study 3) 62.0 (121) 100 (121) 100 (11) 97.9 (48) 100 (46) 96.9 (32)
FIM
Tdap  (Study 1) 54.6 (394) 99.5 (391) 97.0 (166) 94.5 (181) 93.9 (164) 98.4 (128)
Tdap  (Study 3) 59.5 (121) 96.7 (121) 100 (11) 85.4 (48) 97.0 (46) 100 (32)
≥4  × LLOQb
PT
Tdap (Study 1) 22.5 (387) 98.2 (390) 86.1 (166) 76.9 (182) 83.5 (164) 69.7 (109)
Tdap  (Study 3) 32.3 (121) 95.0 (121) 54.5 (11) 72.9 (48) 80.4 (46) 42.9 (28)
FHA
Tdap  (Study 1) 73.9 (394) 100 (391) 98.8 (166) 94.5 (182) 93.9 (164) 92.1 (127)
Tdap  (Study 3) 72.7 (121) 100 (121) 100 (11) 100 (48) 97.8 (46) 90.6 (32)
PRN
Tdap  (Study 1) 26.4 (394) 97.4 (391) 86.7 (166) 88.4 (181) 76.2 (164) 75.2 (129)
Tdap  (Study 3) 30.6 (121) 98.3 (121) 90.9 (11) 89.6 (48) 87.0 (46) 62.5 (32)
FIM
Tdap  (Study 1) 18.5 (394) 97.2 (391) 87.3 (166) 83.4 (181) 78.7 (164) 94.5 (128)
Tdap  (Study 3) 29.8 (121) 94.2 (121) 63.6 (11) 75.0 (48) 76.1 (46) 90.6 (32)
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ia Expressed as the percentage of participants with antibodies at or above the low
b LLOQ = 5 EU/ml for PT, 3 EU/ml for FHA, 3 EU/ml for PRN, and 17 EU/ml for FI
OQ = 3 EU/ml for FHA.
gainst all 4 pertussis antigens between 1 month and 1 year post-
accination followed by a much slower decline between 1 year and
0 years (Fig. 2B).
.  Discussion
These follow-up studies have demonstrated that Tdap vac-
ine induced long-lasting protective antibody responses against
iphtheria and tetanus toxoids and pertussis antigens in both ado-
escents and adults. After antibody concentration peaks observed
t 1 month post-immunization, most of the decreases in antibody
oncentration were observed between 1 month and 1 year post-
mmunization. Between 1 year and 10 years, antibody levels slowly
eclined. Such patterns of antibody persistence have also been
ocumented in adolescents and adults followed for 3 years after
accination with Tdap containing 3 pertussis antigens (PT, FHA, and
RN) [23].
Many adolescents and adults lacked detectable antibody to per-
ussis antigens prior to Tdap vaccination. Over 93% of both age
roups had detectable antibody to FHA (Tables 3 and 5); however,
he proportions of participants with detectable antibodies to other
ertussis antigens were lower: PT ≤ 70% in adolescents and adults;
RN < 75% in adolescents and <61% in adults; and FIM < 77% in ado-
escents and <55% in adults. These results suggest that considerable
umbers of adolescents and adults are susceptible to pertussis as a
esult of waning immunity after childhood immunization. Suscep-
ibility to the bacterium may  be a major factor in the resurgence
f pertussis in the USA and other countries as a result of low vac-
ination coverage of adolescents with acellular pertussis vaccine
oosters [3–7]. Tdap vaccine used in these studies induced excel-
ent antibody responses to all antigens in both adolescents and
dults. Seroprotective antibody levels persisted for 10 years for
lmost all participants against diphtheria and tetanus. Although PT
eropositivity levels had become undetectable in 20–30% of adoles-
ents and 8–18% of adults, over 95% of participants had detectable
ntibody against FHA, PRN, and FIM at 10 years post-vaccination. An
ncrease in the percentage of participants who achieved LLOQ × 4it of quantitation or LLOQ × 4.
 pre-, 1 month, 1, 3, 5 years; for 10 years, LLOQ = 4 EU/ml for PT, PRN, and FIM;
for FIM at 10 years versus 5 years post-vaccination was observed.
This result could be explained by a difference in LLOQ values (17
vs. 3) between the 2 laboratories where the pertussis analysis was
performed.
In summary, antibodies to the antigens in Tdap persisted for 10
years after immunization of adolescents and adults. These results
support the recently reiterated recommendations from the Advi-
sory Committee on Immunization Practices in the United States
that a Tdap booster should be administered to all persons 11–64
years of age [3]. Boosters of Td every 10 years thereafter are also
recommended. Our data indicate that 10 years is also a reasonable
interval for a booster dose of Tdap vaccine. The replacement of Td
vaccine routinely recommended for routine administration every
10 years in adults with Tdap vaccine could reduce the reservoir
of pertussis and could help to protect young infants who are at
greatest risk of pertussis morbidity and mortality.
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